Answers are grounded in this paper and cite their sources.
Review discusses IL-17's role in lung cancer initiation and progression, suggesting therapeutic implications.
Lung cancer continues to present a substantial global health and economic challenge, with consistently high rates of incidence and mortality. While there have been significant strides in precision diagnostics and treatment methods that have contributed to a reduction in mortality over previous years, progress has plateaued recently, largely due to complications such as side effects and resistance to therapies. Emerging research indicates that interleukin-17 (IL-17), a cytokine with pro-inflammatory properties, plays a critical role in various stages of lung cancer, including initiation, growth, invasion, metastasis, angiogenesis, lymphangiogenesis, and treatment resistance. This positions IL-17 as both a crucial regulator and a valuable prognostic marker for the disease’s progression. This review aims to provide an overview of the most recent developments in IL-17 research as it relates to lung cancer, offering a theoretical framework for its potential as a therapeutic target in both the prevention and treatment of lung cancer.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: